Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Diabetic Macular Edema (DME)Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

DRUG

aflibercept 8 mg PFS

Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection

Trial Locations (2)

Retina Consultants of Texas, The Woodlands

Retina Consultants of Texas, Bellaire

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT05989126 - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) | Biotech Hunter | Biotech Hunter